US Patent

US7528143 — Bi-aryl meta-pyrimidine inhibitors of kinases

Composition of Matter · Assigned to TargeGen Inc · Expires 2031-11-16 · 5y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects biaryl meta-pyrimidine compounds that inhibit kinases, such as members of the Jak kinase family.

USPTO Abstract

The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.

Drugs covered by this patent

Patent Metadata

Patent number
US7528143
Jurisdiction
US
Classification
Composition of Matter
Expires
2031-11-16
Drug substance claim
Yes
Drug product claim
Yes
Assignee
TargeGen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.